Form 4: Rigel CFO Sells Shares for Tax Obligations

Rigel Pharmaceuticals' EVP & CFO, Dean L. Schorno, disposed of 3,546 common shares at $34.62 each to cover tax liabilities.

Summary

• Dean L. Schorno, EVP & Chief Financial Officer of Rigel Pharmaceuticals Inc. (RIGL), reported a transaction involving the company's common stock.
• The transaction, dated February 10, 2026, involved the disposition of 3,546 shares of common stock.
• The shares were disposed of at a price of $34.62 per share.
• This transaction was executed under a Rule 10b5-1(c) plan, indicating it was pre-scheduled.
• The transaction code 'F' signifies a payment of tax liability by delivering or withholding securities.
• Following this reported transaction, Mr. Schorno directly owns 55,701 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral event, as the disposition of shares by the CFO was for tax purposes under a pre-arranged plan, not a discretionary sale, and a substantial holding remains.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, indicating it was pre-scheduled and not a discretionary sale based on new, non-public information.
• The disposition was for tax purposes, which is a routine event for executives receiving equity compensation, rather than a voluntary sale of shares.
• Mr. Schorno retains a significant beneficial ownership of 55,701 shares of common stock after this transaction, maintaining alignment with shareholder interests.

Negatives

• A reduction in direct beneficial ownership by a key executive, even if for tax purposes, represents a slight decrease in insider alignment.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those related to tax withholding on equity awards, are common occurrences in the biotechnology and pharmaceutical sectors. These transactions typically do not reflect a change in management's fundamental view of the company's prospects but rather a routine part of equity compensation plans.

Comparison to Industry Standards

• This type of transaction (disposition for tax purposes) is standard practice across industries for executives receiving equity compensation.
• It is not indicative of company-specific performance relative to peers like Pfizer or Johnson & Johnson, but rather a common mechanism for managing tax liabilities associated with vested stock.

Stakeholder Impact

• Shareholders: Minor impact as it's a routine tax-related disposition, not a signal of management's lack of confidence. The executive retains a significant stake.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

The transaction is a routine tax-related disposition by an executive under a pre-arranged plan, not a discretionary sale. It does not provide new fundamental information about the company's prospects to warrant a change in investment thesis. The executive retains a substantial holding, suggesting continued alignment with shareholder interests.

Keywords

Rigel Pharmaceuticals, RIGL, Form 4, Insider Transaction, Dean L. Schorno, CFO, Stock Sale, Tax Withholding, Equity Compensation